What does Simcere Pharmaceutical do?

Simcere, based in Nanjing, researches, makes and sells prescription medicines in China. It already sells drugs such as the cancer treatments Endostar and ENWEIDA, and it has a large pipeline of experimental medicines. The pipeline includes cancer antibodies, antibody-drug conjugates, anti-inflammatory drugs and flu treatments.

Healthcare · Drug Manufacturers - Specialty & Generic · 2096.HK

What Simcere Pharmaceutical Does & How It Makes Money (2096.HK)

Updated October 2026 · reflects Simcere Pharmaceutical's latest reported financials

Chinese drugmaker focused on cancer, immunology, neurology and antiviral medicines. Most revenue comes from selling its pharmaceutical products to distributors, pharmacy chains and other drug manufacturers in China.

Simcere Pharmaceutical's story, moat and numbers — in a 3-minute visual book.

Explore Simcere Pharmaceutical on TacticScale →

How Simcere Pharmaceutical makes money

Most revenue comes from selling its pharmaceutical products to distributors, pharmacy chains and other drug manufacturers in China. It also earns smaller amounts from pharmaceutical ingredients, consulting and technology services, promotion and property management.

What Simcere Pharmaceutical does

Simcere Pharmaceutical Group was founded in 1995 and is headquartered in Nanjing. It develops, manufactures and sells pharmaceutical products in China. Its marketed and late-stage portfolio includes Endostar (recombinant human endostatin), ENWEIDA (envafolimab, a PD-L1 antibody), Leruiping (an IL-4Rα antibody), the JAK1 inhibitor zemprocitinib, the flu drug Xianlinda, which has completed Phase 3, and Sanbexin, with a new injection indication and a sublingual tablet in development. The company's pipeline is deep. Phase 3 candidates include the brain-penetrant oral SERD SIM0270, denlorlatinib and deuterated remdesivir. Its Phase 1 and 2 programs include trispecific antibodies, antibody-drug conjugates (ADCs) targeting CDH6, FGFR2b and CDH17, a pan-RAS inhibitor and an IL-2 mutein fusion protein. More than a dozen further assets are in preclinical work. Simcere earns most of its revenue from product sales to distributors, pharmacies and other manufacturers, with some extra income from ingredients and services.

Products & services

Endostar (recombinant human endostatin injection)
ENWEIDA (envafolimab injection)
Leruiping (anti-IL-4Rα antibody)
Xianlinda (influenza PA inhibitor)
Sanbexin
Enzeshu (suvemcitug for injection)

What is Simcere Pharmaceutical worth?

Fair value: not published

A reliable owner-earnings fair value isn't available for this company yet — we'd rather say so than print a number we don't trust.

We show a fair value only when the method is trustworthy. See Simcere Pharmaceutical on TacticScale →

Sector Healthcare Industry Drug Manufacturers - Specialty & Generic HQ China Ticker 2096.HK Official site

Related companies

CSPC Pharmaceutical (1093.HK) · Shenzhen Chipscreen Biosciences (688321.SS) · Bio-Thera Solutions (688177.SS) · Jiangsu Hengrui Pharmaceuticals (600276.SS)

Understand Simcere Pharmaceutical in 3 minutes →